

Clinical Oversight Review Board (CORB) Criteria for Prescribing Daratumumab (Darzalex)

Non-Formulary **daratumumab (Darzalex)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **Daratumumab (Darzalex)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient is at least 18 years of age
- Diagnosis of multiple myeloma (MM)
- Patient has known intolerance of preferred anti-CD38 agent isatuximab

kp.org

Revised: 03/11/21
Effective: 05/20/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest